Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novavax, FDA and COVID-19
Novavax’s stock slides 16% after FDA puts clinical hold on COVID and flu vaccine candidates
Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.
FDA slaps clinical hold on Novavax' COVID-19 flu combo trial IND
Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the news of a setback for its investigational application for a covid vaccine.
Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines
Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and standalone flu inoculation, sending shares down sharply.
9h
Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
Daily
14h
Novavax faces setback as USFDA halts COVID-Flu vaccine trial over nerve damage report
Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor ...
1d
on MSN
US FDA pauses Novavax's trial of combo flu-COVID shot on safety concerns
The U.S. Food and Drug Administration has placed a hold on trials of Novavax's COVID and influenza combination vaccine, as ...
21h
on MSN
Robinhood, Novavax, Phunware, Lucid Group, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Wednesday, major U.S. indices saw gains, with the Dow Jones Industrial Average climbing nearly 0.8% to 43,077.70.
1d
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
COVID
FDA
flu vaccine
Food and Drug Administration
NVAX
Feedback